Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Biograph Trinion positron emission tomography/computed tomography (PET/CT) system, which made its debut at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, including oncologic, cardiovascular, and neurologic imaging as well as theranostics, according to Siemens Healthineers, the manufacturer of the Biograph Trinion.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, according to Siemens Healthineers, the manufacturer of the newly FDA-cleared PET/CT system. (Image courtesy of Siemens Healthineers.)
The company emphasized that the device’s computer technology is located in the system gantry, allowing a more compact design that can be accommodated in an existing traditional PET/CT room. Siemens Healthineers added that the system’s smart power-save mode for powering down at night, can lead to a 46 percent reduction in energy costs.
“With the Biograph Trinion, Siemens Healthineers is proud to offer customers a high-performance PET/CT scanner that delivers the precision and speed needed for clinical demands,” said James Williams, PhD, head of Molecular Imaging at Siemens Healthineers. “This new system is designed to be user- and patient focused as well as a sustainable investment in terms of reduced installation and operational costs and easy, on-site scalability.”
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.
Study Assesses Amyloid PET/MRI Combination in Detection of Alzheimer’s Disease
July 15th 2024Emerging research revealed that a machine learning combination of amyloid beta PET and structural MRI demonstrated an 89 percent AUC in differentiating between older healthy patients and those with Alzheimer’s disease.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.